Clare Pain is a medical journalist. During the first two years of the pandemic her work involved writing up scientific papers for doctors in Australia – to keep them up to date with the science.

She started to notice some strange changes to the culture of the medical profession and medical journalism in Australia and had increasing doubts about the way the pandemic was being handled by governments. She was particularly disturbed by mandates for vaccination and the TGA’s approach to ivermectin. She left her job in December 2021 which freed her to carry out the Australian Survey of Reasons for COVID-19 Vaccination – a survey of nearly 27,000 people.

Clare’s personal journey includes being laughed at in an Australian hospital in February 2020 for wearing too much PPE (masks and gloves), and anxiously awaiting Covid-19 vaccinations, to January 2022 in Sheffield, England where she tried – unvaccinated – to catch COVID-19 to acquire immunity. It was three months before she was successful.

In this interview we discussed:

• Behind the scenes of medical journalism throughout the pandemic
• The differences between UK and Australian culture
• The Australian ban on Ivermectin for COVID-19
• Pharmaceutical companies’ conflicts of interest
• The Australian Survey of Reasons for COVID-19 Vaccination

Note: The 25 minute long credits to this interview display raw statements from Clare’s survey where Australians shared why they received a C-19 vaccination. The statements on screen are uncensored and do not necessarily represent the views of Discernable or Clare Pain.

CLARITY ON HEALTH SURVEY
https://clarityonhealth.org

Scott Morrison mandate quote
https://www.sbs.com.au/news/article/scott-morrison-says-a-coronavirus-vaccine-would-be-as-mandatory-as-you-can-possibly-make-it/mcg55d7r1

Merck press release on ivermectin
https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic

Merck press release on molnupirivir
https://www.merck.com/news/ridgeback-biotherapeutics-and-merck-announce-preliminary-findings-from-a-phase-2a-trial-of-investigational-covid-19-therapeutic-molnupiravir

FDA Emergency Use Authorisation rules
https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

UK COVID inquiry
https://www.gov.uk/government/publications/uk-covid-19-inquiry-terms-of-reference